-
Ab170691-100μgPalivizumab (anti-RSV-F) is a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab170691-10mgPalivizumab (anti-RSV-F) is a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab170691-1mgPalivizumab (anti-RSV-F) is a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab170691-5mgPalivizumab (anti-RSV-F) is a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
-
Ab177884-100μgPF-06647263 (anti-EFNA4) is a antibody targeting EFNA4.
-
Ab177884-10mgPF-06647263 (anti-EFNA4) is a antibody targeting EFNA4.
-
Ab177884-1mgPF-06647263 (anti-EFNA4) is a antibody targeting EFNA4.
-
Ab177884-5mgPF-06647263 (anti-EFNA4) is a antibody targeting EFNA4.
-
Ab177867-100μgRG7841 (anti-Ly6E) is an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) with potential antineoplastic activity.
-
Ab177867-10mgRG7841 (anti-Ly6E) is an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) with potential antineoplastic activity.
-
Ab177867-1mgRG7841 (anti-Ly6E) is an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) with potential antineoplastic activity.
-
Ab177867-5mgRG7841 (anti-Ly6E) is an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) with potential antineoplastic activity.